Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy


YILDIRIM H. Ç. , GÜVEN D. C. , AKTEPE O. H. , TABAN H., YILMAZ F., YAŞAR S., ...More

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.14744/ejmo.2022.78280
  • Journal Name: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.59-63
  • Keywords: Hyperprogressive disease, immun checkpoint inhibitors, immunotherapy, PILE score
  • Hacettepe University Affiliated: Yes

Abstract

Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD.